Key Drivers
- Clean Balance Sheet
- Strong Cash Flow
- Margin Softening
AIAI Summary
UTHR should now be viewed less as a simple commercial compounder and more as a self-funded pipeline story with a temporarily softer treprostinil franchise, meaning the stock's upside depends on preserving strong cash generation long enough for Tyvaso in IPF, ralinepag, and miroliverELAP to convert into durable new revenue while execution risk and valuation keep multiple compression on the table.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Clean Balance Sheet
- •Strong Cash Flow
- •Margin Softening
UTHR is a financially strong, low-debt company with excellent cash generation and profitability, but softer recent margins, declining liquidity buffers, and a premium valuation limit near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Range fading
- •Failed breakout
- •Near support
Over the last month, UTHR briefly broke to a new high before fading back to the lower end of its range, showing cooling momentum but no clear breakdown yet.
Brief move to a fresh high on 2026-05-06 was not sustained, followed by a drift back into the range
Sentiment & News
Key News Insights:
- •Earnings miss
- •Pipeline focus
- •Insider selling
United Therapeutics missed Q1 EPS and posted slightly lower revenue, but investors remained focused on encouraging pipeline progress and long-term growth catalysts like Tyvaso IPF and ralinepag.
The stock may stay range-bound in the near term as earnings pressure offsets optimism around clinical and strategic growth drivers
Similar Companies in Healthcare
Other companies in the same sector with AI ratings